Make NARCAN Nasal Spray available on U.S. shelves and at online retailers

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 29 Mar 2023
Due: 31 Dec 2023
Delivered: August 2023

Deadline
Met
Late
Not met
Today

What the company said

“Emergent anticipates NARCAN® Nasal Spray will be available on U.S. shelves and at online retailers by the late summer”

SourceEmergent BioSolutions Inc. Form 8-K press release, 2023-03-29
FilingSEC filing index
Deadline as statedlate summer of this year
Deadline used31 Dec 2023, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2023-EBS-002480
Cite as https://keptindex.org/c/KI-C-2023-EBS-002480/ — this address never changes.

What we found

Evidence strength A What the grades mean

Emergent BioSolutions successfully launched the over-the-counter version of NARCAN Nasal Spray, shipping the product to retailers and e-commerce providers nationwide in August 2023, meeting the late summer deadline.

A
Emergent BioSolutions Inc. 10-K filed 2024-03-08 Regulatory filing · published 8 Mar 2024 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 39c9dd939119
“The new OTC product was shipped out to retailers and e-commerce providers nationwide in August of 2023.” ✓ confirmed on the page

Market reaction: the shares moved -16.3% against the S&P 500 over the three sessions around the disclosure (7 Mar 2024 to 12 Mar 2024). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

2 versions

Version 1 · original · stated 29 Mar 2023

Deadline 30 Sep 2023 (“late summer of this year”) · wording expected
Version 2 · stated 30 Aug 2023

Deadline 30 Sep 2023 (“beginning this September”) · wording firm

“NARCAN® Nasal Spray will be the first, life-saving emergency medicine for opioid overdose available on shelves beginning this September”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Product other
Indicative materiality: Low rules
Action: Make
Deliverable: NARCAN Nasal Spray
Where: U.S.
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: Medium
Conditional: Yes: manufacturing changes; supply chain modifications
Depends on: Supplier

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.